B4GALT7
Beta-1,4-galactosyltransferase 7
Also known as: B4GT7_HUMAN, beta4Gal-T7, XGALT-1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UBV7
- Gene
- B4GALT7
- Ensembl
- ENSG00000027847
- Chromosome
- 5
- Canonical length
- 327 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
OverviewNCBI Gene
This gene is a member of the beta-1,4-galactosyltransferase (beta4GalT) family. Family members encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose. Each beta4GalT member has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins, they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus which then remains uncleaved to function as a transmembrane anchor. The enzyme encoded by this gene attaches the first galactose in the common carbohydrate-protein linkage (GlcA-beta1,3-Gal-beta1,3-Gal-beta1,4-Xyl-beta1-O-Ser) found in proteoglycans. This enzyme differs from other beta4GalTs because it lacks the conserved Cys residues found in beta4GalT1-beta4GalT6 and it is located in cis-Golgi instead of trans-Golgi. Mutations in this gene have been associated with the progeroid form of Ehlers-Danlos syndrome. [provided by RefSeq, Oct 2009]
Canonical amino-acid sequenceUniProt
327 residues, UniProt reviewed canonical sequence.
>Q9UBV7|B4GALT7
1 MFPSRRKAAQ LPWEDGRSGL LSGGLPRKCS VFHLFVACLS LGFFSLLWLQ LSCSGDVARA
61 VRGQGQETSG PPRACPPEPP PEHWEEDASW GPHRLAVLVP FRERFEELLV FVPHMRRFLS
121 RKKIRHHIYV LNQVDHFRFN RAALINVGFL ESSNSTDYIA MHDVDLLPLN EELDYGFPEA
181 GPFHVASPEL HPLYHYKTYV GGILLLSKQH YRLCNGMSNR FWGWGREDDE FYRRIKGAGL
241 QLFRPSGITT GYKTFRHLHD PAWRKRDQKR IAAQKQEQFK VDREGGLNTV KYHVASRTAL
301 SVGGAPCTVL NIMLDCDKTA TPWCTFSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against B4GALT7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 43 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 43 nTPM
- choroid plexus: 38 nTPM
- pancreas: 36 nTPM
- pituitary gland: 31 nTPM
- liver: 30 nTPM
- testis: 24 nTPM
Single-cell type
- extravillous trophoblasts: 186 nCPM
- migrating cytotrophoblasts: 55 nCPM
- plasma cells: 53 nCPM
- cytotrophoblasts: 51 nCPM
- decidual stromal cells: 46 nCPM
- syncytiotrophoblasts: 44 nCPM
Immune cell
- intermediate monocyte: 20 nTPM
- non-classical monocyte: 20 nTPM
- myeloid DC: 19 nTPM
- naive B-cell: 19 nTPM
- basophil: 17 nTPM
- classical monocyte: 17 nTPM
Brain region
- midbrain: 46 nTPM
- pons: 46 nTPM
- medulla oblongata: 45 nTPM
- thalamus: 39 nTPM
- choroid plexus: 39 nTPM
- hypothalamus: 39 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about B4GALT7.
Disease | AllUniProt
Conditions B4GALT7 is implicated in, by any mechanism.
- Ehlers-Danlos syndrome, spondylodysplastic type, 1 (EDSSPD1) MIM:130070
Disease | GeneticClinVar
25 pathogenic / likely-pathogenic of 450 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Ehlers-Danlos syndrome progeroid type
- Spondylodysplastic Ehlers-Danlos syndrome
- Ehlers-Danlos syndrome, spondylodysplastic type, 1
- Larsen-like syndrome, B3GAT3 type
- Lethal skeletal dysplasia
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.11
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.31
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- carbohydrate metabolic process
- glycosaminoglycan biosynthetic process
- glycosaminoglycan-protein linkage region biosynthetic process
- negative regulation of fibroblast proliferation
- protein modification process
- protein N-linked glycosylation
- proteoglycan biosynthetic process
- proteoglycan metabolic process
- supramolecular fiber organization
Molecular functions
- beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity
- galactosyltransferase activity
- manganese ion binding
- xylosylprotein 4-beta-galactosyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads B4GALT7 as an antibody target. Whether an autoantibody or antibody against B4GALT7 could matter depends on whether native B4GALT7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
B4GALT7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label B4GALT7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...